Sign In
Buy CVKD
$4.19
-0.160 (-3.68%)
At Close: Jun 03, 2026
PONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #AFib--Cadrenal announces clinical trial initiation plans for tecarfarin in patients with end-stage kidney disease (ESKD) who are transitioning to dialysis
Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness
07:30am, Thursday, 15'th May 2025
PONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #ESKD--Cadrenal announces manufacturing and supply chain milestones for its lead drug, tecarfarin, a novel oral vitamin K antagonist (VKA) anticoagulant.
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update
08:00am, Thursday, 08'th May 2025
PONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #CadrenalTherapeutics--Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update.
Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq
09:40am, Thursday, 17'th Apr 2025
PONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #CadrenalTherapeutics--Cadrenal Therapeutics to present at inaugural Centri Capital Conference at Nasdaq on April 22, 2025.
Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
08:44am, Thursday, 09'th Jan 2025
PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), today announced that Chairman and Chief Executive Officer, Quang X. Pham, will participate in a webcasted fireside chat
PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) today recapped its 2024 milestones and highlighted a clear path forward to develop the investigational drug tecarfarin as
Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook
09:00am, Tuesday, 19'th Nov 2024
Recognized as innovative biopharma developing a potentially safer and superior anticoagulant for patients with implanted cardiac devices and rare cardiovascular conditions PONTE VEDRA, Fla. , Nov. 19,
CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS
09:00am, Tuesday, 12'th Nov 2024
Leading heart failure specialist features tecarfarin data and Cadrenal's proposed clinical trial protocol at 8th EACTS Mechanical Circulatory Support Summit PONTE VEDRA, Fla. , Nov. 12, 2024 /PRNewswi
CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE
09:00am, Thursday, 07'th Nov 2024
PONTE VEDRA, Fla. , Nov. 7, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) (the "Company" or "Cadrenal"), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin
Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
08:00pm, Friday, 01'st Nov 2024
PONTE VEDRA, Fla., Nov. 1, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., ("Cadrenal" or the "Company") (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral a
Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility
09:00am, Thursday, 24'th Oct 2024
PONTE VEDRA, Fla. , Oct. 24, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) (the "Company" or "Cadrenal"), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin
CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM
09:00am, Wednesday, 23'rd Oct 2024
Participation Reinforces Cadrenal's Commitment to Innovation, Education and Improved Patient Outcomes with Anticoagulation Therapy PONTE VEDRA, Fla. , Oct. 23, 2024 /PRNewswire/ -- Cadrenal Therapeuti
Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference
04:15pm, Monday, 23'rd Sep 2024
PONTE VEDRA, Fla. , Sept. 23, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed
Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients
09:00am, Thursday, 22'nd Aug 2024
PONTE VEDRA, Fla. , Aug. 22, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K Antagonist (VKA
Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients
09:00am, Tuesday, 20'th Aug 2024
Analysis features the growing need to evolve anticoagulation therapy beyond warfarin to avoid gastrointestinal bleeding, a significant and common complication for left ventricular assist device (LVAD
